Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04080505 · ClinicalTrials.gov registry record · Phase 3
Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy?
A Phase 3 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 29
- Enrollment target
NCT04080505 is a Phase 3 study that was terminated before completion, run by Columbia University. The registered enrollment target is 29 participants.
The verdict
NCT04080505, a Phase 3 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this research is to find out if SSKI (Potassium Iodide) reduces vascularity (the number and concentration of blood vessels) and improves how well patients do after surgery for removal of their whole thyroid gland in Graves' disease (an autoimmune disease that is a common cause of hyperthyroidism).
Interventions
- DRUG SSKI- Potassium Iodide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2015-02-10 |
| Est. Completion | 2023-03-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04080505
The ClinicalTrials.gov registry entry for NCT04080505 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SSKI- Potassium Iodide is the first listed.
NCT04080505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04080505 about?
NCT04080505 is a clinical study titled "Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy?". The purpose of this research is to find out if SSKI (Potassium Iodide) reduces vascularity (the number and concentration of blood vessels) and improves how well patients do after surgery for removal of their whole thyroid gland in Graves' disease (an autoimmune disease that is a common cause of hype...
What is the current status of trial NCT04080505?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 29 participants. The study started on 2015-02-10. Estimated completion is 2023-03-03.
What interventions are being tested in trial NCT04080505?
The interventions under investigation include: SSKI- Potassium Iodide (DRUG).
Who is sponsoring clinical trial NCT04080505?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.